



周晓燕 博士，教授

硕士生导师，赣江青年学者

● **教育和工作背景**

- 2003/09-2008/06 华中科技大学同济医学院，病理学与病理生理学，医学博士（硕-博连读）；
- 2008/06-2013/12 南昌大学基础医学院，病理生理学教研室，讲师
- 2014/01-2019/12 南昌大学基础医学院，病理生理学教研室，副教授
- 2016/09-2017/09 波士顿大学医学院，生物化学与分子生物学系，访问学者；
- 2020/12-至今 南昌大学基础医学院，病理生理学教研室，教授

● **研究兴趣、领域：**

课题组主要致力于研究肝纤维化发病机制及防治策略。近年来主持各级课题共计 11 项，其中国家自然科学基金 3 项；以通讯作者在国内外较有影响力的杂志上发表科研论文 30 篇。

● **学术兼职：**

中国病理生理学会会员，江西省生理学会常务理事

● **主要成果、荣誉、奖励：**

1. Qu XQ, Chen QF, Shi QQ, Luo QQ, Zheng SY, Li YH, Bai LY, Gan S, **Zhou XY (周晓燕, Corresponding Author)**. Hepatocyte-Conditional Knockout of Phosphatidylethanolamine Binding Protein 4 Aggravated LPS/D-GalN-Induced Acute Liver Injury via the TLR4/NF- $\kappa$ B Pathway. *Front Immunol.* 2022; 13: 901566. DOI: 10.3389/fimmu.2022.901566. IF:8.786
2. Luo QQ, Ling YY, Li YF, Qu XQ, Shi QQ, Zheng SY, Li YH, Huang YH, **Zhou XY (周晓燕, Corresponding Author)**. Phosphatidylethanolamine-Binding Protein 4 Deficiency Exacerbates Carbon

- 
- Tetrachloride-Induced Liver Fibrosis by Regulating the NF- $\kappa$ B Signaling Pathway. *Front Pharmacol.* 2022; 964829. DOI:10.3389/fphar.2022.964829. IF:5.988
3. Xu F, Zhang JM, **Zhou XY (周晓燕, Corresponding Author)**, Hua Hao. Lipoxin A4 and its analog attenuate high fat diet-induced atherosclerosis via Keap1/Nrf2 pathway. *Exp Cell Res* 2022;412(1):113025. DOI: 10.1016/j.yexcr.2022.113025
  4. Zhang JM, **Zhou XY (周晓燕, Corresponding Author)**, Hua Hao. Macrophage phenotype-switching in cancer. *Eur J Pharmacol.* 2022; 931:175229. DOI: 10.1016/j.ejphar.2022.175229.
  5. Zhang T, Hao H, Zhou ZQ, Zeng T, Zhang JM, **Zhou XY (周晓燕, Corresponding Author)**. Lipoxin A4 inhibited the activation of Hepatic Stellate Cells-T6 cells by modulating profibrotic cytokines and NF- $\kappa$ B signaling pathway. *Prostaglandins Other Lipid Mediat.* 2020;146:106380.
  6. Luo ZK, Chen QF, Qu XQ, **Zhou XY (周晓燕, Corresponding Author)**. The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors. *Onco Targets Ther.* 2019 Sep 18;12:7685-7690.
  7. Zhang T, Hao H, **Zhou XY (周晓燕, Corresponding Author)**. The role of lipoxin in regulating tumor immune microenvironments. *Prostaglandins Other Lipid Mediat.* 2019 Oct;144:106341.
  8. Chen QF, Hao H, Kuang XD, Hu QD, Huang YH, **Zhou XY (周晓燕, Corresponding Author)**. BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system. *Prostaglandins Other Lipid Mediat.* 2019;140:9-1
  9. Chen QF, Kuang XD, Yuan QF, Hao H, Zhang T, Huang YH, **Zhou XY (周晓燕, Corresponding Author)**. Lipoxin A4 attenuates lipopolysaccharide-induced acute lung injury via activation of the ACE2-Ang-(1-7)-Mas axis. *Innate Immun.* 2018;24(5):285-296.
  10. Hu QD, Hu ZZ, Chen QF, Huang YH, Mao Z, **Zhou XY (周晓燕) (Corresponding Author)**. BML-111 equilibrated ACE-AngII-AT1R and ACE2-Ang-(1-7)-Mas axis to protect hepatic fibrosis in rats. *Prostaglandins Other Lipid Mediat.* 2017;131:75-82.

---

联系方式:

电话: 18007092139

E-mail: [zhouxiaoyan@ncu.edu.cn](mailto:zhouxiaoyan@ncu.edu.cn)